Quantcast

Latest Bosentan Stories

2011-05-04 09:45:00

WESTMINSTER, Colo., May 4, 2011 /PRNewswire/ -- Plato BioPharma, Inc. (PBI) and Gilead Sciences, Inc.

2011-04-09 04:09:18

A new study has demonstrated no significant benefit of taking the drug bosentan for idiopathic pulmonary fibrosis (IPF).

2010-10-20 07:15:00

MUMBAI, India, October 20, 2010 /PRNewswire-FirstCall/ -- Cipla, among the world's leading generic pharmaceutical companies, has introduced Pirfenidone in India under the brand name Pirfenex, for the treatment of IPF. A chronic progressive form of lung disease, IPF has average survival rates as low as 3-5 years which is less than many cancers.

2010-08-25 07:00:00

SOUTH SAN FRANCISCO, Calif., Aug. 25 /PRNewswire/ -- Actelion Pharmaceuticals US, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved the brand name VELETRI® for the company's epoprostenol for injection therapy.

2010-06-28 10:30:00

SILVER SPRING, Md. and SOUTH SAN FRANCISCO, Calif., June 28 /PRNewswire/ -- The Pulmonary Hypertension Association (PHA) and Actelion Pharmaceuticals US, Inc. today announced Actelion has been named the recipient of the 2010 Corporation of the Year Award.

2010-06-09 08:00:00

WALTHAM, Mass., June 9 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that while United Therapeutics' Tyvaso and Adcirca--launched in 2009--are each prescribed by more than half of surveyed pulmonologists in the specialized pulmonary arterial hypertension (PAH) center setting, Adcirca is much more widely used than Tyvaso among surveyed non-PAH-center physicians. The new Physician & Payer Forum...

2010-05-17 10:35:00

NEW ORLEANS, May 17 /PRNewswire-FirstCall/ -- Actelion Ltd (SIX: ATLN) announced today that findings from the REVEAL® (Registry to EValuate Early And Long-term PAH Disease Management) Registry have confirmed the clinical utility of the REVEAL risk score calculator, a new tool designed to predict 1-year survival in patients with pulmonary arterial hypertension (PAH) according to data presented at the American Thoracic Society's (ATS) Annual International Conference.

2010-04-22 05:00:00

SOUTH SAN FRANCISCO, Calif., April 22 /PRNewswire/ -- Actelion Pharmaceuticals US, Inc.

2009-11-17 11:05:07

Research team reviews outcomes after 2 years of treatment with ambrisentan.


Word of the Day
ecotone
  • A transitional zone between two communities containing the characteristic species of each.
The word 'ecotone' comes 'eco-' plus a Greek root meaning 'tension'.